At Fridays close Alexion Pharmaceuticals (ticker: ALXN) ended the day 5.32% on approximately double its average trading volume. Although the reason for this fall isn't due to a company-specific event, we can attribute this to what has been a weak earnings season. With ALXN due to report Q3 earnings on October 24th, investors may be speculating a ALXN miss. In addition, despite not having any direct competitors, Cubist Pharmaceuticals (ticker: CBST), another niche market biotech player, traded down on lower than expected revenue estimates. While many are uncertain, we remain positive on ALXN's ability to continue to "beat and raise" estimates.
No comments:
Post a Comment